Trident Lifeline (BSE: TLL) had a P/E of 21.0× on 6 Nov 2026, below the industry P/E of 27.6×. Its ROCE of 22% is the second-highest among its 7 Pharmaceutical Retailers peers, and sales and net profit grew 60% and 47% a year over 3 years. Its dividend yield is 0.2%, and debt is 0.74× equity. It is listed on an SME platform with a market cap of ₹495 Cr, ranked 4th of 8 Pharmaceutical Retailers companies by market cap; the shares rose 41% over the past year.
- ₹423.95
- ₹423.95
- ₹412.00
- ₹422.50
- 4.8K
Health check
- ReturnsAhead
+40.8% over a year, better than 7 of 7 peers.
- Price tagCheaper
P/E 21.0 vs industry 27.6.
- GrowthSteady
Sales +59.7%, profit +46.8% a year over 3 years.
- ProfitabilityStrong
ROCE 21.8% vs peer median 5.2%.
- Balance sheetFair
Debt 0.74× equity, interest covered 6.2×, Piotroski 4 of 9.
- Red flagsNone found
No warning signs in the headline numbers.
Small cap
Market sensitivity
Key metrics
- Market cap
- ₹495 Cr
- Small cap
- P/E
- 21.0
- Industry 27.6
- Price to book
- 4.22
- Peers 2.61
- Dividend yield
- 0.24%
- ROE
- 23.6%
- Peers 8.0%
- ROCE
- 21.8%
- Peers 5.2%
- Debt to equity
- 0.74
- Debt ₹90 Cr
- EPS (TTM)
- ₹19.72
- OPM (TTM)
- 22.8%
- Net margin 14.6%
- Sales growth
- +50.3%
- Latest quarter vs a year ago
- Profit growth
- +33.3%
- Latest quarter vs a year ago
- Price to sales
- 3.09
- EV/EBITDA 14.2
Strengths and risks
Strengths
- Return on equity of 23.6%.
- Return on capital employed of 21.8%.
- Quarterly profit up 33.3% on a year ago.
- Quarterly sales up 50.3% on a year ago.
About Trident Lifeline
Trident Lifeline Limited, together with its subsidiaries, manufactures and markets finished doses in India, Ghana, Kenya, Peru, Cameroon, Venezuela, and internationally. It provides various medicinal products, including pharmaceuticals, nutraceuticals, herbals, and injectables in the form of tablets, capsules, dry powders for oral suspension, oral liquids, ointments, liquid ointments, effervescent tablets, sachets, pastes, gels, solutions, suspensions,…
- Headquarters
- Surat
- Employees
- 46
- Sector
- Healthcare
- ISIN
- INE0MKA01014
- Website
- tridentlifeline.com
Price range
- Avg volume (3M)
- 44K
- 1-year return
- plus 40.8%
- From 52-week high
- minus 6.4%
Peers · Pharmaceutical Retailers
| Company | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MEDPLUSMedplus Health Services | 604.60 | plus 0.66% | 7,260 | 34.3 | 3.47 | 12.2% | 10.8% | 4.2% | 14.7% | 64.0% | 0.00% | minus 25.7% |
| HEALTHXHealth X Platform | 272.55 | minus 0.42% | 867 | – | 1.35 | −0.2% | 0.2% | −4.4% | 8.0% | – | 0.00% | minus 8.3% |
| ONEGLOBALOne Global Service Provider | 365.45 | minus 7.66% | 714 | 9.7 | 5.06 | 65.7% | 65.3% | 19.2% | 201.8% | 269.3% | 0.23% | minus 32.0% |
| TLLTrident Lifeline | 413.75 | minus 2.07% | 495 | 21.0 | 4.22 | 21.8% | 23.6% | 22.8% | 59.7% | 46.8% | 0.24% | plus 40.8% |
| ACHYUTAchyut Healthcare | 7.76 | plus 4.86% | 187 | 776.0 | 5.45 | 1.1% | 1.0% | 2.2% | 62.6% | 10.9% | 0.00% | plus 28.7% |
| MAITRIMaitri Enterprises | 31.20 | plus 0.32% | 14 | 37.6 | 2.61 | 19.9% | 12.1% | 5.4% | 35.8% | – | 0.00% | minus 11.4% |
| MULLERMuller & Phipps (India) | 193.80 | plus 3.11% | 12 | – | −5.82 | 1.8% | – | −17.2% | 12.9% | – | 0.00% | minus 23.9% |
| DPLDipna Pharmachem | 4.31 | plus 1.65% | 11 | 10.5 | 0.18 | 5.2% | 5.2% | 21.2% | 7.7% | 2.2% | 0.00% | minus 78.4% |
| Median of 7 peers | – | 0.66% | 187 | 34.3 | 2.61 | 5.2% | 8.0% | 4.2% | 14.7% | 37.5% | 0.00% | −23.9% |
Quarterly results
| ₹ Cr | Jun 25 | Sep 25 | Mar 26 | Jun 26 | Sep 26 |
|---|---|---|---|---|---|
| 23.6 | 31.3 | 75.7 | 33.7 | 47.1 | |
| – | – | – | +42.8% | +50.3% | |
| 18.4 | 24.5 | 59.6 | 25.2 | 35.8 | |
| 5.2 | 6.9 | 16.1 | 8.5 | 11.3 | |
| 21.9% | 21.9% | 21.3% | 25.3% | 24.1% | |
| 1.4 | 1.7 | 6.2 | 0.6 | 1 | |
| 1.1 | 1 | 2 | 0.9 | 1.9 | |
| 1.5 | 0.9 | 3.7 | 1.6 | 1.6 | |
| 3.9 | 6.6 | 16.6 | 6.6 | 8.8 | |
| 29.2% | 23.2% | 31.2% | 23.3% | 25.1% | |
| 3.1 | 4.9 | 11 | 5 | 6.6 | |
| – | – | – | +64.2% | +33.3% | |
| 2.66 | 4.27 | 9.45 | 4.27 | 5.69 |
Profit & loss
- Sales CAGR 3Y
- +59.7%
- Profit CAGR 3Y
- +46.8%
- EPS CAGR 3Y
- +37.9%
- ROE
- 23.6%
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 31.7 | 44.6 | 87 | 129 | |
| – | +40.8% | +94.9% | +48.4% | |
| 25.1 | 35.3 | 70 | 98.8 | |
| 6.6 | 9.3 | 17 | 30.2 | |
| 20.7% | 20.8% | 19.5% | 23.4% | |
| 1 | 1.6 | 1.8 | 3.9 | |
| 0.4 | 0.6 | 3.8 | 5.2 | |
| 0.4 | 1 | 5.5 | 6.1 | |
| −0.3 | −0.6 | 4.1 | 4.4 | |
| 6.6 | 8.7 | 13.6 | 27.2 | |
| 8.6% | 31.7% | 22.9% | 29.0% | |
| 6 | 6.3 | 11.7 | 19 | |
| – | +5.5% | +85.2% | +62.1% | |
| 6.22 | 5.52 | 10.22 | 16.32 |
Forecast
Balance sheet
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 11.5 | 11.5 | 11.5 | 11.9 | |
| 34.1 | 41.4 | 53 | 88.5 | |
| 7.7 | 18.4 | 54 | 73 | |
| 9.2 | 15.8 | 37.5 | 63.4 | |
| 62.6 | 87.1 | 156 | 237 | |
| 5.4 | 20.9 | 36.5 | 60.1 | |
| 4.8 | 4.5 | 1.6 | 17.5 | |
| – | 0.2 | 0.2 | 0.2 | |
| 13.8 | 6.7 | 2.5 | 4.2 | |
| 38.6 | 54.9 | 115 | 155 | |
| 62.6 | 87.1 | 156 | 237 |
Cash flow
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| −19 | 2.2 | −4 | 4.7 | |
| −9.7 | −20.4 | −13.8 | −36.6 | |
| 42.3 | 11 | 13.5 | 33.7 | |
| 13.6 | −7.1 | −4.3 | 1.8 | |
| −6.9 | −17.9 | −11.1 | −36.5 | |
| −25.9 | −15.7 | −15.1 | −31.8 |
Shareholding pattern
This company is listed only on BSE, so there’s no NSE category split. See Major shareholders below for the named holders.
Major shareholders
Filings & events
News
No recent news coverage found.